DAY ONE BIOPHARMACEUTICALS ($DAWN) posted quarterly earnings results on Tuesday, August 5th. The company reported earnings of -$0.29 per share, beating estimates of -$0.36 by $0.07. The company also reported revenue of $33,910,000, missing estimates of $36,006,642 by $-2,096,642.
You can see Quiver Quantitative's $DAWN stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
DAY ONE BIOPHARMACEUTICALS Insider Trading Activity
DAY ONE BIOPHARMACEUTICALS insiders have traded $DAWN stock on the open market 7 times in the past 6 months. Of those trades, 0 have been purchases and 7 have been sales.
Here’s a breakdown of recent trading of $DAWN stock by insiders over the last 6 months:
- JEREMY BENDER (CHIEF EXECUTIVE OFFICER) has made 0 purchases and 2 sales selling 26,012 shares for an estimated $231,515.
- ADAM DUBOW (GENERAL COUNSEL) has made 0 purchases and 2 sales selling 9,198 shares for an estimated $84,066.
- CHARLES N II YORK (COO, CFO AND SECRETARY) has made 0 purchases and 2 sales selling 8,652 shares for an estimated $79,074.
- LAUREN MERENDINO (Chief Commercial Officer) sold 3,927 shares for an estimated $24,574
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
DAY ONE BIOPHARMACEUTICALS Hedge Fund Activity
We have seen 108 institutional investors add shares of DAY ONE BIOPHARMACEUTICALS stock to their portfolio, and 71 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FAIRMOUNT FUNDS MANAGEMENT LLC removed 3,103,448 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $24,610,342
- POLAR CAPITAL HOLDINGS PLC added 2,165,000 shares (+1170.3%) to their portfolio in Q1 2025, for an estimated $17,168,450
- TIMESSQUARE CAPITAL MANAGEMENT, LLC removed 1,710,926 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $13,567,643
- ALYESKA INVESTMENT GROUP, L.P. added 1,547,577 shares (+61.6%) to their portfolio in Q1 2025, for an estimated $12,272,285
- BRAIDWELL LP removed 1,337,000 shares (-27.4%) from their portfolio in Q1 2025, for an estimated $10,602,410
- JANUS HENDERSON GROUP PLC removed 1,284,920 shares (-98.4%) from their portfolio in Q1 2025, for an estimated $10,189,415
- VESTAL POINT CAPITAL, LP added 1,158,127 shares (+80.4%) to their portfolio in Q1 2025, for an estimated $9,183,947
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
DAY ONE BIOPHARMACEUTICALS Analyst Ratings
Wall Street analysts have issued reports on $DAWN in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Needham issued a "Buy" rating on 05/07/2025
- HC Wainwright & Co. issued a "Buy" rating on 04/03/2025
- Goldman Sachs issued a "Buy" rating on 03/25/2025
- JP Morgan issued a "Overweight" rating on 03/05/2025
- Wedbush issued a "Outperform" rating on 02/26/2025
To track analyst ratings and price targets for DAY ONE BIOPHARMACEUTICALS, check out Quiver Quantitative's $DAWN forecast page.
DAY ONE BIOPHARMACEUTICALS Price Targets
Multiple analysts have issued price targets for $DAWN recently. We have seen 5 analysts offer price targets for $DAWN in the last 6 months, with a median target of $32.0.
Here are some recent targets:
- Ami Fadia from Needham set a target price of $27.0 on 05/07/2025
- Andres Maldonado from HC Wainwright & Co. set a target price of $36.0 on 04/03/2025
- Andrea Tan from Goldman Sachs set a target price of $27.0 on 03/25/2025
- Anupam Rama from JP Morgan set a target price of $34.0 on 03/05/2025
- Robert Driscoll from Wedbush set a target price of $32.0 on 02/26/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
